3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
2
Phase 3
1
Status
Completed
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
3
Myeloid
3
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Neoplastic Processes
1
Myeloproliferative Disorders
1
Leukemia
1
Hematologic Diseases
1
Bronchiolitis Obliterans Syndrome
1
Bone Marrow Diseases
1
Interventions
pembrolizumab
9
trastuzumab deruxtecan
5
trametinib
4
dabrafenib
4
zanubrutinib
3
nilotinib
3
fludarabine
3
Trastuzumab
3
Dexamethasone
3
Cyclophosphamide
3
tucatinib
2
tisagenlecleucel
2
selinexor
2
relatlimab
2
pemigatinib
2
larotrectinib
2
ipatasertib
2
erdafitinib
2
entrectinib
2
enfortumab vedotin
2
defactinib
2
daratumumab
2
blinatumomab
2
binimetinib
2
belzutifan
2
axicabtagene ciloleucel
2
atezolizumab
2
TIC10 compound
2
Sunitinib
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
Has announcements
×
nilotinib
×
Clear all
NCT01784068
2025-09-10
ENESTfreedom
Novartis
Phase 2
Completed
215 enrolled
7 charts
1 FDA
NCT01698905
2025-09-02
ENESTop
Novartis
Phase 2
Completed
163 enrolled
7 charts
1 FDA
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA